

Proteomics of Human Body Fluids

Proteomics of Human Body Fluids

Principles, Methods, and Applications

Edited by

Visith Thongboonkerd, MD, FRCPT


*Medical Molecular Biology Unit
Office for Research and Development
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand*

HUMANA PRESS  TOTOWA, NEW JERSEY

© 2007 Humana Press Inc.
999 Riverview Drive, Suite 208
Totowa, New Jersey 07512

All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher.

All papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher.

This publication is printed on acid-free paper. 
ANSI Z39.48-1984 (American Standards Institute)

Permanence of Paper for Printed Library Materials.

Cover design by Karen Schulz

For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; E-mail: orders@humanapr.com; or visit our Website: www.humanapress.com

Photocopy Authorization Policy:

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US \$30.00 per copy is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [978-1-58829-657-3/07 \$30.00].

Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1

eISBN 978-1-59745-432-2

Library of Congress Cataloging in Publication Data

Proteomics of human body fluids : principles, methods, and applications
/ edited by Visith Thongboonkerd.

p. ; cm.

Includes bibliographical references and index.

ISBN: 978-1-58829-657-3 (alk. paper)

1. Body fluids—Analysis. 2. Proteins—Analysis. 3. Proteomics.

I. Thongboonkerd, Visith.

[DNLM: 1. Body Fluids—chemistry. 2. Body Fluids—secretion.

3. Proteome—analysis. 4. Proteomics—methods. QU 105 P967 2007]

RB52.P765 2007

616.07'56—dc22

2006025679

Preface

Rapid growth of the “proteomics” field during the past twelve years has contributed to significant advances in science. To date, proteomic technologies have been widely applied to examining various kinds of biological materials. Clinical proteomics is the concept of using proteomic techniques to evaluate the proteomes in clinical samples for biomarker discovery and for better understanding of normal physiology and pathogenic mechanisms of human diseases. Translating the proteomic information to clinical practice may lead to the ultimate goals of earlier diagnosis, improved therapeutic outcome and successful prevention of diseases.

Human body fluids are produced, secreted, and/or excreted from various tissues or organs. Major compositions of body fluids are water, organic substances and inorganic compounds. These compositions vary in each body fluid, making one’s function different from the others. Analyses of protein components in individual fluids would increase current knowledge on the biology and physiology of various organ systems, and on the pathophysiology of diseases, which cause alterations in protein production, secretion, and/or excretion from the affected tissues or organs into the body fluids. Additionally, human body fluids are the main targets and valuable sources for biomarker discovery. As the high-throughput capability and applicability of proteomics for analyzing proteins in the body fluids have been already proven, these desires are most likely achievable by using proteomic technologies.

Proteomics of Human Body Fluids: Principles, Methods, and Applications is the first and nearly complete collection of applications of proteomics to analyze various human body fluids, including plasma, serum, urine, cerebrospinal fluid, pleural effusion, bronchoalveolar lavage fluid, sputum, nasal lavage fluid, saliva, pancreatic juice, bile, amniotic fluid, milk, nipple aspirate fluid, seminal fluid, vitreous fluid, dialysate, and ultrafiltrate yielded during renal replacement therapy. The book has been divided into two main parts. The first part provides basic principles and strategies for proteomic analysis of human body fluids, written by the leading experts in the proteomics field. The second part offers more details regarding methodologies, recent findings and clinical applications of proteomic analysis of each specific type of human body fluids, written by the authorities in their respective fields. Perspectives and future directions of each subject are also discussed. This book, therefore, covers almost everything one needs to know about proteomics of human body fluids.

I would like to thank all the authors who have contributed to this book, which would not be possible without their willingness to give the valuable time from their tight schedule and to share their knowledge and experience. I hope that the book will prove to be a useful source of references for all who are interested in this rapidly growing field of science and that the information inside this book will facilitate the progress of current and future studies on the human body fluid proteomes.

Visith Thongboonkerd, MD, FRCPT

Contents

Preface	v
Contributors	ix

PART I: PRINCIPLES OF PROTEOMICS APPLIED TO HUMAN BODY FLUIDS

1 Proteomic Strategies for Analyzing Body Fluids <i>Sung-Min Ahn and Richard J. Simpson</i>	3
2 Sample Preparation of Body Fluids for Proteomics Analysis <i>Natalia Govorukhina and Rainer Bischoff</i>	31
3 Multiplexed Immunoassays for Protein Profiling in Human Body Fluids <i>Silke Wittemann, Dominic P. Eisinger, Laurie L. Stephen, and Thomas O. Joos</i>	71
4 Deciphering the Hieroglyphics of Functional Proteomics Using Small Molecule Probes <i>Wayne F. Patton</i>	83
5 Modification-Specific Proteomic Analysis of Glycoproteins in Human Body Fluids by Mass Spectrometry <i>Jakob Bunkenborg, Per Häggglund, and Ole Nørregaard Jensen</i>	107
6 Plasma Proteome Database <i>Malabika Sarker, G. Hanumanthu, and Akhilesh Pandey</i>	129
7 2D PAGE Databases for Proteins in Human Body Fluids <i>Christine Hoogland, Khaled Mostaguir, Jean-Charles Sanchez, Denis F. Hochstrasser, and Ron D. Appel</i>	137
8 Bioinformatics and Experimental Design for Biomarker Discovery <i>Marc R. Wilkins and Sybille M. N. Hunt</i>	147
9 Integrative Omics, Pharmacoproteomics, and Human Body Fluids <i>K. K. Jain</i>	175

PART II: PROTEOMIC ANALYSIS OF SPECIFIC TYPES OF HUMAN BODY FLUIDS: METHODS, FINDINGS, APPLICATIONS, PERSPECTIVES, AND FUTURE DIRECTIONS

10 The Human Plasma and Serum Proteome <i>Gilbert S. Omenn, Rajasree Menon, Marcin Adamski, Thomas Blackwell, Brian B. Haab, Weimin Gao, and David J. States</i>	195
---	-----

11	Proteomics of Human Urine <i>Visith Thongboonkerd, Pedro R. Cutillas, Robert J. Unwin, Stefan Schaub, Peter Nickerson, Marion Haubitz, Harald Mischak, Dobrin Nedelkov, Urban A. Kiernan, and Randall W. Nelson</i>	225
12	Proteomics of Human Cerebrospinal Fluid <i>Margareta Ramström and Jonas Bergquist</i>	269
13	Proteomics of Pleural Effusion <i>Joost Hegmans, Annabrita Hemmes, and Bart Lambrecht</i>	285
14	Proteomics of Bronchoalveolar Lavage Fluid and Sputum <i>Ruddy Wattiez, Olivier Michel, and Paul Falmagne</i>	309
15	Proteomics of Sinusitis Nasal Lavage Fluid <i>Begona Casado, Simona Viglio, and James N. Baraniuk</i>	327
16	Proteomics of Human Saliva <i>Francisco M. L. Amado, Rui M. P. Vitorino, Maria J. C. Lobo, and Pedro M. D. N. Domingues</i>	347
17	Proteomics of Human Pancreatic Juice <i>Mads Grønberg, Anirban Maitra, and Akhilesh Pandey</i>	377
18	Proteomics of Human Bile <i>Troels Z. Kristiansen, Anirban Maitra, and Akhilesh Pandey</i>	399
19	Proteomics of Amniotic Fluid <i>David Crettaz, Lynne Thadikaran, Denis Gallot, Pierre-Alain Queloz, Vincent Sapin, Joël S. Rossier, Patrick Hohlfeld, and Jean-Daniel Tissot</i>	415
20	Proteomics of Human Milk <i>Amedeo Conti, Maria Gabriella Giuffrida, and Maria Cavaletto</i>	437
21	Proteomics of Nipple Aspirate Fluid in Nonlactating Women <i>Edward R. Sauter</i>	453
22	Proteomics of Seminal Fluid <i>Benjamin Solomon and Mark W. Duncan</i>	467
23	Proteomics of Vitreous Fluid <i>Atsushi Minamoto, Ken Yamane, and Tomoko Yokoyama</i>	495
24	Proteomics of Human Dialysate and Ultrafiltrate Fluids Yielded by Renal Replacement Therapy <i>Michael Walden, Stefan Wittke, Harald Mischak, and Raymond C. Vanholder, for the European Uremic Toxin Work Group (EUTox)</i>	509

Index	521
-------------	-----

Contributors

- MARCIN ADAMSKI • *Michigan Proteomics Alliance for Cancer Research, Center for Computational Medicine and Biology, University of Michigan Medical School, Ann Arbor, MI. Present address: Faculty of Biological and Chemical Sciences, Integrative Biology School, The University of Queensland, Brisbane, Australia*
- SUNG-MIN AHN • *Joint ProteomicS Laboratory, Ludwig Institute for Cancer Research & the Walter and Eliza Hall Institute of Medical Research, P.O. Box 2008, Royal Melbourne Hospital Parkville, Victoria 3050, Australia*
- FRANCISCO M. L. AMADO • *Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal*
- RON D. APPEL • *Proteome Informatics Group, Swiss Institute of Bioinformatics and Computer Science Department, University of Geneva, Geneva, Switzerland*
- JAMES N. BARANIUK • *Proteomics Laboratory, Georgetown University, Washington, DC*
- JONAS BERGQUIST • *Department of Chemistry, Analytical Chemistry, Uppsala University, Uppsala, Sweden*
- RAINER BISCHOFF • *University of Groningen, Center of Pharmacy, Department of Analytical Biochemistry, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands*
- THOMAS BLACKWELL • *Michigan Proteomics Alliance for Cancer Research, Center for Computational Medicine and Biology, University of Michigan Medical School, Ann Arbor, MI*
- JAKOB BUNKENBORG • *Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark*
- BEGONA CASADO • *Proteomics Laboratory, Georgetown University, Washington, DC; and Department of Biochemistry “A Castellani”, University of Pavia, Italy*
- MARIA CAVALETTO • *Department of Environment and Life Sciences, University of Piemonte Orientale, Alessandria, Italy*
- AMEDEO CONTI • *National Council of Research—Institute of Science of Food Production, Section of Torino, Italy*
- DAVID CRETTEZ • *Service Régional Vaudois de Transfusion Sanguine, Lausanne, Switzerland*

- PEDRO R. CUTILLAS • *Ludwig Institute for Cancer Research, University College London Branch; and Department of Biochemistry and Molecular Biology, University College London, London, UK*
- PEDRO M. D. N. DOMINGUES • *Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal*
- MARK W. DUNCAN • *Division of Endocrinology, Metabolism & Diabetes, Department of Pediatrics, University of Colorado Cancer Center Proteomics Core, University of Colorado Health Sciences Center, Denver, CO*
- DOMINIC P. EISINGER • *Upstate USA, Lake Placid, NY*
- PAUL FALMAGNE • *Department of Proteomics and Protein Biochemistry, 6 Avenue du Champs de Mars, University of Mons-Hainaut, B-7000, Belgium*
- DENIS GALLOT • *Unité de Médecine Materno-Fœtale, Hôtel-Dieu, CHU, Clermont-Ferrand, France*
- WEIMIN GAO • *Michigan Proteomics Alliance for Cancer Research. Present address: The Institute of Environmental and Human Health, Department of Environmental Toxicology, Texas Tech University, Lubbock, TX*
- MARIA GABRIELLA GIUFFRIDA • *National Council of Research—Institute of Science of Food Production, Section of Torino, Italy*
- NATALIA GOVORUKHINA • *University of Groningen, Center of Pharmacy, Department of Analytical Biochemistry, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands*
- MADS GRØNBORG • *McKusick-Nathans Institute of Genetic Medicine and Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD; and Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, Odense M, Denmark*
- BRIAN B. HAAB • *Michigan Proteomics Alliance for Cancer Research, Van Andel Research Institute, Grand Rapids, MI*
- PER HÄGGLUND • *Biochemistry and Nutrition Group, Biocentrum DTU 224-124, Technical University of Denmark, DK-2800 Kgs, Lyngby, Denmark*
- G. HANUMANTHU • *Institute of Bioinformatics, Bangalore, India*
- MARION HAUBITZ • *Department of Nephrology, Medizinische Hochschule Hannover, D-30623 Hannover, Germany*
- JOOST HEGMANS • *Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands*
- ANNABRITA HEMMES • *Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands*
- DENIS F. HOCHSTRASSER • *Clinical Chemistry Laboratory, Geneva University Hospital, Geneva, Switzerland*
- PATRICK HOHLFELD • *Département de Gynécologie et Obstétrique, CHUV, Lausanne, Switzerland*

- CHRISTINE HOOGLAND • *Proteome Informatics Group, Swiss Institute of Bioinformatics, Geneva, Switzerland*
- SYBILLE M. N. HUNT • *Proteome Systems, Locked Bag 2073, North Ryde 1670, Sydney, Australia*
- K. K. JAIN • *Jain PharmaBiotech, Blaesiring 7, CH-4057 Basel, Switzerland*
- OLE NØRREGAARD JENSEN • *Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark*
- THOMAS O. JOOS • *NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany*
- URBAN A. KIERNAN • *Intrinsic Bioprobes, Inc., 625 S. Smith Road, Suite #22, Tempe, AZ*
- TROELS Z. KRISTIANSEN • *McKusick-Nathans Institute of Genetic Medicine and Department of Biological Chemistry, Johns Hopkins University, Baltimore, MD; and Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, Odense M, Denmark*
- BART LAMBRECHT • *Department of Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands*
- MARIA J. C. LOBO • *High Institute of Health Sciences-North, Department of Dental Sciences, 4585-116 Gandra PRD, Portugal*
- ANIRBAN MAITRA • *McKusick-Nathans Institute of Genetic Medicine, The Sol Goldman Pancreatic Cancer Research Center, and Departments of Biological Chemistry, Pathology and Oncology, Johns Hopkins University, Baltimore, MD*
- RAJASREE MENON • *Michigan Proteomics Alliance for Cancer Research, Center for Computational Medicine and Biology, University of Michigan Medical School, Ann Arbor, MI*
- OLIVIER MICHEL • *Clinical of Allergology and Respiratory Diseases, CHU Saint-Pierre- ULB. Brussels, B-1000, Belgium*
- ATSUSHI MINAMOTO • *Department of Ophthalmology and Visual Science, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Japan*
- HARALD MISCHAK • *Mosaiques Diagnostics and Therapeutics AG, Mellendorfer Str. 7, D-30625 Hannover; and Department of Nephrology, Medizinische Hochschule Hannover, D-30623 Hannover, Germany*
- KHALED MOSTAGUIR • *Proteome Informatics Group, Swiss Institute of Bioinformatics, Geneva, Switzerland*
- DOBRIN NEDELKOV • *Intrinsic Bioprobes, Inc., 625 S. Smith Road, Suite #22, Tempe, AZ*
- RANDALL W. NELSON • *Intrinsic Bioprobes, Inc., 625 S. Smith Road, Suite #22, Tempe, AZ*

- PETER NICKERSON • *Manitoba Centre for Proteomics; and Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada*
- GILBERT S. OMENN • *Michigan Proteomics Alliance for Cancer Research, Center for Computational Medicine and Biology, Departments of Internal Medicine and Human Genetics, University of Michigan Medical School, Ann Arbor, MI*
- AKHILESH PANDEY • *McKusick-Nathans Institute of Genetic Medicine, and Departments of Biological Chemistry, Oncology and Pathology, Johns Hopkins University, Baltimore, MD*
- WAYNE F. PATTON • *Biochemistry Department, PerkinElmer Life and Analytical Sciences, 549 Albany Street, Boston, MA*
- PIERRE-ALAIN QUELOZ • *Service Régional Vaudois de Transfusion Sanguine, Lausanne, Switzerland*
- MARGARETA RAMSTRÖM • *Department of Chemistry, Analytical Chemistry, Uppsala University, P.O. Box 599, SE-751 24 Uppsala, Sweden*
- JOËL S. ROSSIER • *DiagnoSwiss SA, Monthey, Switzerland*
- JEAN-CHARLES SANCHEZ • *Biomedical Proteomics Research Group, Geneva University Hospital, Geneva, Switzerland*
- VINCENT SAPIN • *Laboratoire de Biochimie Médicale, INSERM U.384, CHU, Clermont-Ferrand, France*
- MALABIKA SARKER • *Institute of Bioinformatics, Bangalore, India*
- EDWARD R. SAUTER • *Department of Surgery, University of Missouri, Columbia, MO*
- STEFAN SCHAUB • *Manitoba Centre for Proteomics, Winnipeg, MB, Canada; and Department for Transplant Immunology and Nephrology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland*
- RICHARD J. SIMPSON • *Joint ProteomicS Laboratory, Ludwig Institute for Cancer Research & the Walter and Eliza Hall Institute of Medical Research, P.O. Box 2008, Royal Melbourne Hospital Parkville, Victoria 3050, Australia*
- BENJAMIN SOLOMON • *Division of Endocrinology, Metabolism & Diabetes, Department of Pediatrics, University of Colorado Cancer Center Proteomics Core, University of Colorado Health Sciences Center, Denver, CO*
- DAVID J. STATES • *Michigan Proteomics Alliance for Cancer Research, Center for Computational Medicine and Biology, Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI*
- LAURIE L. STEPHEN • *Upstate USA, Lake Placid, NY*
- LYNNE THADIKKARAN • *Service Régional Vaudois de Transfusion Sanguine, Lausanne, Switzerland*
- VISITH THONGBOONKERD • *Medical Molecular Biology Unit, Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand*

- JEAN-DANIEL TISSOT • *Service Régional Vaudois de Transfusion Sanguine, Lausanne, Switzerland*
- ROBERT J. UNWIN • *Centre for Nephrology and Department of Physiology, Royal Free and University College Medical School, University College London, London, UK*
- RAYMOND C. VANHOLDER • *Nephrology Section, Department of Internal Medicine, University Hospital, Gent, Belgium*
- SIMONA VIGLIO • *Department of Biochemistry “A Castellani”, University of Pavia, Italy*
- RUI M. P. VITORINO • *Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal*
- MICHAEL WALDEN • *Mosaiques Diagnostics and Therapeutics AG, Mellendorfer Str. 7, D-30625 Hannover, Germany*
- RUDDY WATTIEZ • *Department of Proteomics and Protein Biochemistry, 6 Avenue du Champs de Mars, University of Mons-Hainaut, B-7000, Belgium*
- MARC R. WILKINS • *School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW 2052, Australia*
- SILKE WITTEMANN • *NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany*
- STEFAN WITKE • *Mosaiques Diagnostics and Therapeutics AG, Mellendorfer Str. 7, D-30625 Hannover, Germany*
- KEN YAMANE • *Department of Ophthalmology and Visual Science, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Japan*
- TOMOKO YOKOYAMA • *Department of Ophthalmology and Visual Science, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Japan*

I

**PRINCIPLES OF PROTEOMICS APPLIED
TO HUMAN BODY FLUIDS**

Proteomic Strategies for Analyzing Body Fluids

Sung-Min Ahn and Richard J. Simpson

Summary

The rapid development of molecular and cell biology in the latter part of the last century has led us to the understanding that many diseases, including cancer, are caused by perturbations of cellular networks, which are triggered by genetic changes and/or environmental challenges. These perturbations manifest by changing cellular protein profiles, which, in turn, alter the quantitative relationship of tissue-specific proteins shed into the tissue/organ microenvironment. Such altered protein expression profiles in body fluids constitute molecular signatures or fingerprints that reflect the original perturbation of cellular networks. The exciting challenge of modern proteomics is to identify such signatures for various disease states—then the body fluids will become windows into disease and potential biospecimen sources for biomarkers of disease. (1).

Key Words: Body fluids; biomarkers; proteome; expression proteomics; targeted proteomics; sample collection; enrichment; prefractionation.

1. Introduction

1.1. Historical Perspective and Biological Context

Claude Bernard, the 19th century physiologist, introduced the concept of *milieu intérieur* or the internal environment, defining it as the circulating organic liquid that surrounds and bathes all tissue elements (2). Bernard regarded extracellular fluid as the internal environment of the body and emphasized the importance of maintaining the constancy of that environment. This notion still holds true today, especially in the era of proteomics. Indeed, the detection of protein perturbations in the internal environment is one of the major goals of the fledgling field of proteomics.

Approximately 60% of the adult human body is fluid, which is mainly distributed between two compartments: the extracellular space and the intracellular




Fig. 1. Overview of body fluids and the internal environment. In an average 70-kg person, the total body water is about 60% of the body weight (approx 42.0 L). The intracellular fluid constitutes about two-thirds of the total body water (approx 28.0 L), whereas the extracellular fluid constitutes the rest (approx 14.0 L). The interstitial fluid comprises more than 75% of the extracellular fluid (approx 11.0 L), whereas plasma comprises the remaining 25% (approx 3.0 L) (3).

space (3). The extracellular fluid is broadly divided into the interstitial fluid and the blood plasma, which can be referred to as the microenvironment and the macroenvironment, respectively (Fig. 1). Tissues consist of cellular elements (parenchymal and stromal cells) and extracellular elements (extracellular matrix and tissue interstitial fluid). In the literature, the term *tissue microenvironment* usually refers to both cellular and extracellular elements (4). In this chapter, however, microenvironments are limited to tissue interstitial fluid (TIF) only, which surrounds and bathes tissues. Since parenchyma, stroma, and blood all contribute to the microenvironment, their individual secreted or shed protein profiles are reflected together in the overall protein profile of the microenvironment. The microenvironment, the interstitial fluid, is in direct contact with cells, exchanging molecules with the intracellular fluid, whereas the macroenvironment, the plasma, continuously communicates with all microenvironments throughout the body, delivering nutrients and signals and receiving feedback directly or indirectly via the lymphatics.




Fig. 2. Relationship between plasma and other body fluids. Tissue interstitial fluid (TIF) enters terminal lymphatics and becomes lymph. (Thus, the composition of lymph in the terminal lymphatics is almost identical to that of TIF.) Hence, all lymph in the body empties into the venous system at the junctures of internal jugular veins and subclavian veins (94). CSF is secreted from the choroid plexus at a rate of about 500 mL/d, which is approximately three to four times as much as its total volume (about 150 mL). Excess CSF is absorbed by the arachnoid villi, which have vesicular holes large enough to allow the free flow of CSF, proteins, and even particles as large as red and white blood cells into the venous system (95). Since lymph and CSF drain into the blood, theoretically all proteins in lymph and CSF are present in the blood. For this reason, lymph and CSF proteomes are considered subproteomes of the plasma. Other body fluids such as urine and tears represent plasma to varying extents while having unique characteristics of their own.

Plasma is important in any proteomic analysis of human body fluids, not only because every cell in the body leaves a record of its physiological state in the products it sheds into the blood (5), but also because it influences most other body fluids. Therefore, it is important to understand the proteomes of various body fluids in the context of plasma. Theoretically, lymph and cerebrospinal fluid (CSF) proteomes are subproteomes of plasma since these body fluids eventually drain into plasma. Other body fluids represent plasma to varying extents while having unique characteristics of their own (Fig. 2).

1.2. Differential Enrichment of Biomarkers in Body Fluids

One of the main challenges of proteomics is to find molecular signatures or biomarkers of disease. In plasma, high-abundance proteins such as albumin and transferrin constitute approx 99% of the total protein and the remaining 1% is assumed to include many potential biomarkers that are typically of low abundance (6). Therefore, removal of high-abundance proteins has become a common practice to enrich for low-abundance proteins in plasma. (This issue will be discussed in more details later in this chapter, as well as in other chapters.) However, before trying to remove high-abundance proteins from plasma, the concept of differential enrichment of biomarkers in various body fluids needs to be considered. **Figure 3** illustrates a simplified relationship of the concentration of secreted or membrane-shed cellular proteins in TIF, lymph, and blood. For example, if there is a cancer in the sigmoid region of the colon, cancer cells will secrete or shed cancer-specific proteins into the microenvironment. Such proteins traffic from the TIF to the lymph, being diluted during the process. Lymph fluids from various regions of the body merge and eventually drain into the circulatory system. Approximately 2.5 L of lymph drains into the systemic circulation per day, whereas about 3 L of plasma (approx 5 L of blood) is ejected from the heart every minute. Therefore, the dilution factor is at least 1.5×10^3 . (Lymph fluids from different tissues have different tissue-specific proteins. This additional consideration is not included here). Given that only a 10-fold enrichment can be achieved by removing the top six most abundant proteins in plasma, the advantage of using TIF (7) or lymph (8) rather than plasma seems considerable in discovering biomarkers. For example, the study of Sedlaczek and colleagues (9) highlights the differential enrichment of CA125, an ovarian cancer marker, in different body fluids from patients with ovarian carcinoma. **Table 1** summarizes their comparative analysis of CA125 in sera, cyst fluids, and ascites. According to this study, the median value of CA125 is approx 64-fold higher in cyst fluid than in serum.

Malignant ascites is another example of differential enrichment of secreted or membrane-shed proteins. Some cancers such as colorectal and ovarian cancers can be seeded onto peritoneal cavity and cause malignant ascites via various mechanisms. According to Trape and colleagues (10), carcinoembryonic antigen (CEA) levels in malignant ascites are in the range of 33,540 ng/mL maximum, which is more than 5×10^3 -fold higher than the normal plasma level of CEA (<5 ng/mL). Although the availability of clinical specimens often becomes the bottleneck of body fluid research owing to a paucity of clinical specimens and ethical considerations, understanding and utilizing the differential enrichment of biomarkers may open a new window of opportunity for discovering otherwise undetectable low-abundance biomarkers.




Fig. 3. Dilution of tissue-specific proteins in TIF, lymph, and blood.

Table 1
Median Levels of Ca125 in Serum, Cyst Fluid, and Ascites
From Patients With Ovarian Neoplasms

Histologic type	CA125 (U/mL)		
	Serum	Ascites	Cyst fluid
Serous carcinoma	696.0	18,563.0	44,850.0
Endometroid carcinoma	661.0	14,415.5	32,150.0
Mucinous adenocarcinoma	67.0	3521.5	3930.5
Undifferentiated carcinoma	860.7	3909.5	—
Serous cystadenoma	7.1	—	42150.0
Serous cyst	4.8	—	6851.5
Mucinous adenoma	10.8	—	5691.5

From Sedlacek et al. (9), with permission.

2. Proteomic Approaches for Studying Human Body Fluids

Proteomics, a newly emerging postgenomic technology that allows one to unravel the biological complexity encoded by the genome at the protein level, is built on technologies that allow one to analyze large numbers of proteins in a single experiment. Broadly, there are two main facets of proteomics research:

1. *Expression proteomics*, which aims to catalog the proteome, i.e., the full complement of proteins expressed by the genome in any given cell, tissue, or body fluid at a given time.




Fig. 4. Pipeline of technologies used in the field of proteomics. The overall success of qualitative and quantitative proteomics relies on the success of the individual technologies involved in a proteomic pipeline. PTMs, posttranslational modifications.

2. *Targeted proteomics*, which strives to determine the cellular functions of genes directly at the protein level (e.g., protein-protein interactions, posttranslational modifications, protein localizations within cells) (*11*).

Currently, the major focus of proteomics of body fluids is expression proteomics, especially the quantitative differences in protein profiles between physiological and pathological states.

Figure 4 summarizes the pipeline of technologies that comprise the field of proteomics strategies. Each step in the pipeline involves defined technologies, each of which is technically challenging and of equal importance. Needless to say, the overall success of any proteomics research depends on the success of the individual step in the proteomic pipeline. For solving specific biological questions, the combination of various options in each step provides much flexibility in experimental design. In this chapter, we address current issues and technologies involved in each step of proteomics with an emphasis on their application to body fluid research.

2.1. Biospecimen Collection and Storage

Success in proteomics very much depends on careful biospecimen preparation. In clinical chemistry, many factors are known to cause variations in biospecimen precollection, collection, and postcollection stages (*12*). Therefore, a standardized protocol for sample collection, processing, and storage is essential for reproducible experiments within a given laboratory and, especially, from one laboratory to another. (When we compare a large set of data from different laboratories, it is important that we are actually comparing “apples with apples!”). This was one of the major technical issues addressed in the pilot phase of the Human Plasma Proteome Project, the first systematic international effort devoted to analyzing a body fluid (*13*).

Among the various body fluids, blood is the most sampled and studied, yet its optimal sample preparation is still problematic. For proteomic analysis, blood can be collected as serum or plasma. When blood is removed from the body and allowed to clot, it separates into a solid clot containing blood cells and fibrin, and a liquid phase termed serum. If an anticoagulant such as heparin or EDTA is added, the liquid phase is termed plasma (12). From a clinical chemistry perspective, serum differs from plasma only in that it lacks fibrinogen. From a proteomics perspective, however, the differences between serum and plasma can be considerable. The physiological and biochemical difference between serum and plasma is demarcated by the activation of the coagulation cascade, which involves the sequential activation of proteases (14). The activated proteases during this process will in turn have proteolytic effects on other proteins. According to a recent report of the Human Plasma Proteome Organisation (HUPO), a significant number of peptides differed between serum and plasma specimens (especially intracellular, coagulation-dependent, and enzymatic activity-derived peptides) (15). The issue of coagulation can also be applied to other body fluids. Extravascular coagulations are observed in lymph (16) and synovial fluid (17), and it is likely that most of the internal body fluids have coagulation factors from blood to some extent.

Hulmes and colleagues (18) have addressed questions regarding plasma collection, stabilization, and storage procedures for proteomic analysis of clinical samples. According to their research, addition of a protease inhibitor cocktail directly to plasma collection tubes prior to phlebotomy, centrifugation within 1 h of blood draw, snap-freezing aliquots immediately in a dry ice/alcohol bath, and storing frozen aliquots in a -70°C freezer can improve sample qualities for proteomic analysis. This recommendation is supported in the report of the HUPO Plasma Proteome Project on specimen collection and handling (15).

There are a number of anticoagulants that prevent the coagulation of blood. In clinical chemistry, EDTA, heparin, and citrate are the most widely used, and the choice of anticoagulants is important since the manner in which they behave differs. Unlike EDTA and heparin, citrate is used as a concentrated solution in a ratio of 1 part to 9 parts of blood (19), which itself introduces dilution effects and variation. Heparin is a highly charged molecule, thus being able to prevent binding of molecules to charged surfaces (15). Although EDTA can interfere with assays when divalent cations are necessary, it does not have dilution effects nor does it interfere with charged molecules. Therefore, EDTA seems to be the anticoagulant of choice for proteomic analysis of body fluids when the primary aim is to catalog and quantitate proteins. However, the choice of anticoagulants may also depend on the specific aim or protein targets of experiments since anticoagulants can affect the stability of some proteins, if not all (e.g., osteocalcin) (20,21). Heparin, citrate, and EDTA have been reported to yield no obvious m/z (mass per charge) peaks in typical proteome analysis, yet some types of blood

collection tubes designed to reduce protein degradation contain aprotinin or other protease inhibitors that will appear as m/z peaks and pose a potential problem with the interpretation of mass spectra if they are not recognized as exogenous additives to a specimen (22).

With regard to the use of protease inhibitors, all data from the HUPO Plasma Proteome Project on specimen collection and handling are consistent with the benefits of blocking protease activity and, perhaps more importantly, of blocking this activity immediately, during sample acquisition (15).

Finally, the limitations of current storage methods using -70 to -80°C freezers are worth mentioning. It has been reported that some degree of degradation occurs over time in coagulation factors of stored plasma samples, presumably owing to renewal of enzymatic activity, albeit minimal, even at -80°C (23). In this context, Rouy and colleagues (24) reported that the plasma level of metalloproteinase-9 (MMP-9) decreased by 90% after 2 yr of storage at -80°C , whereas those of MMP-2 remained constant. It is surprising that two enzymes, which share many properties, behave in different manners under the same storage condition. Therefore, careful validation and interpretation are essential when we analyze a large set of body fluid samples stored in tissue banks over a period of time since at least some proteins may show different levels of stability. Topics relating to specimen collection and storage of other body fluids are dealt with in other chapters of this book.

2.2. Sample Loading: How and What to Compare

Typically, when cell or tissue lysates are subjected to proteomic analysis, equal amounts of protein are compared (e.g., 100 μg protein from each sample for 2D electrophoresis [2-DE]). In body fluid research, however, the analysis of samples based on equal protein load may cause serious problems because even the normal interval of total protein levels is very wide (e.g., it ranges from 68.0 to 86.0 mg/mL in plasma). To illustrate this potential problem, let us consider these two hypothetical patients.

Patient A

Total plasma protein	86 mg/mL
CEA	4.9 ng/mL

Patient B

Total plasma protein	68 mg/mL
CEA	4.9 ng/mL

(CEA is a tumor marker for colorectal cancer; the normal range is <5 ng/mL.)

In current medical practice, total plasma protein levels are not considered when we interpret individual protein levels (i.e., they are treated as independent variables). Therefore, CEA levels of both patients will be regarded as normal.




Fig. 5. Volume-based vs protein quantity-based comparison. Left panel illustrates the comparison of the same volumes of plasma from patients A and B. Total protein levels differ, yet carcinoembryonic antigen (CEA) levels are the same. If we were to analyze the same quantities of proteins instead (i.e., 86 μg of protein for each patient), patterns will look like the right panel. In this case, total protein levels are the same (since we loaded the same quantities), yet CEA levels differ. When the same quantities of samples are compared, it is assumed that the total protein levels in patients' plasma are more or less identical. This assumption does not hold true for most body fluids.

Now, let us assume that we perform 2-DE using plasma from these two patients and that the dynamic range of detection is approx 10^{12} . (In reality, it is about 10^4 .) Then, to load 86 μg of each sample to immobilized pH gradient (IPG) strips, we load 1 μL of plasma for patient A, which contains 4.9 μg of CEA, and 1.26 μL of plasma for patient B, which contains 6.2 μg of CEA. After 2-DE, the CEA spots will be selected as differentially expressed spots. (Differential gel electrophoresis [DIGE] can detect quantitative changes as low as 10% [25]). In this approach, over 20% of variation is introduced because the interpretation of CEA levels is dependent on total protein levels. In other words, CEA levels or other biomarker levels, which we try to detect, can vary according to the total protein concentrations (**Fig. 5**).

When we deal with cell or tissue lysate, the situation is totally different. For example, if we compare radiation-treated with nontreated CaCo2 cell lines using 2-DE, we are trying to detect changes in essentially identical systems, and loading the same amount of samples (e.g., 100 μg protein from each sample) will be a reasonable way to guarantee equal comparison.

There are two ways of solving this problem. The first is by simply loading the same volume of body fluids. Although this method is perfectly compatible with the current practice of clinical laboratories, it may not be an ideal solution for expression proteomics of body fluids wherein prefractionation, such as depletion of high-abundance proteins, is commonly required. When depletion is used, for example, volumetric information is difficult to preserve and invariably lost. If we

use multiple affinity columns for depleting high-abundance proteins, volumetric information pertaining to original samples would be lost, first, by dilution during chromatographic separation and, second, by a desalting and concentrating step.

The second solution is to normalize data based on the total protein concentrations. This method provides information about relative concentration of proteins, and data can be normalized even after extensive prefractionation since quantitative information is easier to preserve.

Let us go back to the example of CEA above. In that example, more than 20% of variation was introduced just because we loaded the same quantities of protein from each sample assuming, willingly or unwillingly, that total protein levels of two samples were identical. This systematic variation can be easily corrected by calculating a normalization factor from total protein levels of each sample and applying it to the data.

If we select the sample from patient A as a baseline, the normalization factor will be 68 mg/mL divided by 86 mg/mL. Then, the CEA level of patient B will be corrected to be 4.9 pg by multiplying the compensation factor to the original data $[(68/86) \times 6.2 = 4.9]$.

If we keep track of quantitative information in each prefractionation step, it is possible to calculate proper normalization factors. For example, after depleting high-abundance proteins using affinity chromatography, we can get information about how much protein is depleted from the total proteome (e.g., 85% is depleted), which can be used for normalizing data.

2.3. Prefractionation and Fractionation

The development of proteomics technologies has enabled us to analyze a large number of proteins simultaneously. 2-DE, arguably the most widely used separation technique in proteomics (26,27), can resolve more than 5000 proteins in one gel and detect less than 1 ng of proteins per spot (28). Nevertheless, at least two technical challenges need to be overcome before proteomics can realize its full potential for protein expression profiling of body fluids. First, body fluids contain an enormous number of proteins. For example, it is claimed that plasma alone contains more than 1 million protein forms (6). Another important consideration is the problem of the dynamic range of protein abundances (29). In plasma, the dynamic range of protein abundances can extend up to 12 orders of magnitude (30), which far exceeds the current dynamic range of 2-DE (approx 10^4) (31). To circumvent these problems, good separation strategies are essential. The essence of prefractionation is the enrichment of the target population of proteins (e.g., removal of high-abundance proteins and/or the isolation of subpopulation of proteins—e.g., glycoproteins, phosphoproteins, glycosylphosphatidylinositol (GPI)-anchored proteins, cysteine-containing proteins) whereas the essence of fractionation is the maximal separation of a complex protein

mixture into its individual components (e.g., 2-DE and multidimensional chromatography). Prefractionation and fractionation technologies are too complicated for a single review. For more detailed reviews, see Simpson (32) and Righetti et al. (33).

2.3.1. Reduction of Dynamic Range of Protein Abundances

Various human body fluids including plasma, CSF, ascites, and lymph are characterized by the presence of high-abundance proteins, which preclude effective analysis of low-abundance proteins (akin to searching for “needles” in a haystack). For example, 22 high-abundance proteins represent about 99% of the total proteins in plasma (34). Therefore, in any proteomic strategy for analyzing body fluids, the reduction of the dynamic range of protein abundances must be addressed in order to “drill down” to the low-abundance proteins for analysis. Two opposite approaches will be briefly introduced here. One approach reduces the dynamic range by depleting high-abundance proteins; the other achieves the goal by increasing the relative copy numbers of low-abundance proteins. These two may be called the *yin* and *yang* approaches to reducing the dynamic range of protein abundances.

2.3.1.1. YIN APPROACH OF REDUCING DYNAMIC RANGE OF PROTEIN ABUNDANCES

2.3.1.1.1. *Depletion of High-Abundance Proteins.* Depletion of high-abundance proteins is probably the most commonly used prefractionation technique for body fluid research. (Govorukhina and Bischoff discuss it in more detail in Chapter 2.) As just mentioned, this approach aims to reduce the dynamic range of protein abundances by removing high-abundance proteins, and it has been successfully adopted for body fluid research. For example, Pieper and colleagues (35) have shown that immunoaffinity subtraction chromatography can improve the resolution of low-abundance proteins in plasma. Although this approach is very useful in body fluid research, there are two issues that require careful consideration. The first is the limitation of this approach, which becomes evident if we take albumin, a major high-abundance protein in various body fluids, with about 50 mg/mL in plasma, as an example (36). If any depletion strategy were able to remove 99.9% of albumin from the plasma (according to a recent report, the efficiency ranges from 96.0 to 99.4% [37]), the remaining (contaminating) concentration of albumin would still be approx 50 μ g/mL. This concentration is 1×10^4 fold higher than CEA levels (approx 5 ng/mL) and 5×10^6 fold higher than levels of interleukin-6 (IL-6; approx 10 pg/mL). Considering that the current dynamic range of 2-DE is approx 10^4 (31), this simple comparison shows that in addition to the depletion of high-abundance proteins, technologies for the efficient separation and

enrichment of low-abundance proteins to detectable levels have to be further utilized and developed (38).

The second issue is the possibility that depletion of high-abundance proteins may diminish the chances of finding low-abundance proteins bound to and carried by high-abundance carrier proteins such as albumin (39). Although this concept is still controversial and has not proved its importance, we should be careful not to lose extra information when subtracting a portion of proteome before initial analysis.

2.3.1.2. YANG APPROACH OF REDUCING DYNAMIC RANGE OF PROTEIN ABUNDANCES

2.3.1.2.1. Reduction of Dynamic Range With a Peptide Library. This approach (enrichment of the general population of proteins to the same degree) involves constructing a large peptide library via combinatorial chemistry. Using just 20 natural amino acids and making six reaction steps, 20^6 peptide ligands can be made; owing to this enormous diversity, there is theoretically a ligand for every protein, antibody, and peptide. When a complex protein mixture such as plasma is incubated with this library under large overloading conditions, high-abundance proteins saturate their specific affinity ligands and excess is removed during the washing step, whereas low-abundance proteins continue to concentrate on their specific affinity ligands. After processing, the eluate has all the representatives of the original mixture, but with much reduced dynamic range since high-abundance proteins are significantly diluted and low-abundance proteins are concentrated (33). Although the efficiency and efficacy of this approach are not yet clear in this early stage, it is free from potential problems associated with depletion and may work as a complementary method to depletion strategy.

2.3.1.2.2. Reduction of Dynamic Range With Selective Capture Methods. This approach involves enrichment of the selective population of proteins. The peptide library mentioned in **Subheading 2.3.1.2.1.** reduces the dynamic range of protein abundances by enriching the general population of proteins to the same degree. There are, however, other methods by which we can enrich selective populations of proteins using the unique characteristics of each group. Here, we briefly introduce two examples, which are important for analyzing body fluids.

Immunoprecipitation is the most classical example of enriching a selective population of proteins. This technique is based on the immunoaffinity between antibodies and their target proteins. Immunoprecipitation has been successfully applied to the analysis of protein isoforms, phosphorylated proteins, and protein-protein complexes (33).

Glycoprotein capture is another good example. This method, specifically targeting glycoproteins, is highly relevant to body fluid research, since protein

glycosylation is prevalent in extracellular proteins, and many clinical biomarkers in body fluids are also glycoproteins (40). Currently, there are two main approaches for capturing glycoproteins. Kaji and colleagues (41) combined the classical lectin chromatography with isotope-coded tagging and mass spectrometry (MS). In this method, glycopeptides, generated by tryptic digestion of protein mixture, are captured by the lectin column. Then captured glycopeptides are isotope-tagged with ^{18}O and identified by multidimensional liquid chromatography (LC) MS. In the other approach, Zhang and colleagues (40) used hydrazide chemistry to capture glycoproteins through conjugation, which is followed by isotope labeling and identification/quantitation by tandem mass spectrometry (MS/MS).

2.3.2. Electrophoresis and Liquid Chromatography

Electrophoresis and liquid chromatography are two main streams of separation technology. In this section, only a limited number of topics will be discussed, with an emphasis on their application to body fluids. For more detailed reviews, see Westermeier and Grona (42), Simpson (43), and Mant and Hodges (44).

2.3.2.1. ISOELECTRIC FOCUSING

Proteins are amphoteric molecules that carry a positive, negative, or zero net charge, depending on the pH of their surroundings. Therefore, when placed in a pH gradient within an electric field, proteins will migrate to the pH where they have no net charge. Isoelectric focusing (IEF) takes advantage of this phenomenon (45).

In addition to its well-known application as the first dimension analysis of 2-DE, IEF can also be used as a prefractionation technique or in combination with non-gel-based technologies such as liquid chromatography. Here we will briefly introduce three applications of IEF: prefractionation IEF for narrow-range IPGs, free-flow electrophoresis (FFE), and chromatofocusing.

2.3.2.1.1. Prefractionation-IEF for Narrow-Range Immobilized pH Gradients.

The use of multiple narrow overlapping IPGs is the best remedy for increasing the resolution of 2-DE to avoid multiple proteins in a single spot for unambiguous protein identification and to facilitate the application of higher protein amounts for the detection of minor components (46).

When narrow-range IPGs are loaded with a body fluid (e.g., plasma), a massive disturbance of the focusing process ensues, stemming from two main problems. The first problem is that it is usually not possible to achieve high loads of protein, actually focused, on narrow pH gradients since most of the loaded proteins have pI s outside the pH range of the IPG. The second problem is the severe disturbance caused by extraneous proteins, which migrate to the

ends of the strip, where they collect in highly concentrated zones in charged states. Therefore, it is essential to prefractionate body fluids into isoelectric fractions that correspond to the pH ranges of the IPGs (47).

To achieve this goal, various liquid-phase IEF apparatus such as the Rotofor™ (48), the multicompartiment electrolyzer (49), and the zoom fractionator (50) have been developed. In general, these apparatus, except the Rotofor, have multiple compartments separated by separation barriers with a defined pH, and the pH range of a fraction in a compartment is determined by the pH of separation barriers at both ends. After IEF, each fraction can be loaded to corresponding narrow-pH IPG strips. For a more detailed discussion of each technique, see Righetti et al. (33) and Zuo and Speicher (51). Recently, Tang and colleagues (52) reported on four-dimensional analysis, which combines the depletion of high-abundance proteins, liquid-phase IEF, and 1-DE, followed by nanocapillary reversed phase high-performance liquid chromatography (RP-HPLC) tryptic peptide separation prior to MS/MS analysis to detect low-abundance proteins in human plasma and serum.

Görg and colleagues (53) developed a solid-phase prefractionation IEF using granulated gels. In brief, a Sephadex slurry is made with Sephadex G-200 superfine and a solution containing urea, 3-[(3-cholamidopropyl)dimethylamino]-1-propanesulfonate (CHAPS), dithiothreitol (DTT), and carrier ampholytes. This slurry is mixed with the sample solution, and the mixture is pipeted into the trough of the template inserted into the IPG DryStrip kit for IEF. After IEF, individual Sephadex fractions are removed with a spatula and applied onto rehydrated, narrow-pH-range IPG strips. When IPG-IEF is performed, prefractionated proteins in the Sephadex fraction are electrophoretically transferred to IPG strips and focused. This method does not require special equipment and is relatively free from protein dilution and loss, which may occur in liquid-phase IEF.

2.3.2.1.2. Free-Flow Electrophoresis and Chromatofocusing. Although the prefractionation-IEF methods introduced above are specifically devised for 2-DE, FFE, and chromatofocusing, they provide better results in combination with liquid chromatography; they can also be used with gel-based technologies. Both FFE and chromatofocusing are liquid-phase IEF, and, as their names indicate, the basic principles of FFE and chromatofocusing are based on electrophoresis and chromatography, respectively.

In FFE, samples are continuously injected into a carrier ampholyte solution flowing as a thin film between two parallel plates. By introducing an electric field perpendicular to the flow direction, proteins are separated by IEF according to their different *pI* values and collected (29,54). Key advantages of this method are improved sample recovery (owing to the absence of solid membrane

supports) and sample loading capacity. (Sample loading is continuous during FFE and hence not rate limiting [29]).

Although FFE can be coupled off-line to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (54), the restricted separation capacity of SDS-PAGE presents limitations in resolution, recovery of low- M_r proteins, and sample loadability. In contrast, when FFE is coupled off-line to RP-HPLC, the high resolving power produced in the first-dimension IEF step, in which very narrow-range pH gradients can easily be generated, coupled to the high resolution of modern RP-HPLC stationary phases, extends the resolving power of this 2D protein separation system over other previously described 2D systems based solely on coupled HPLC columns (29). For the fundamental principles and experimental protocols of FFE, including the introduction of commercial instrumentation, see Krivankova and Bocek (55) and Weber et al. (56). For a detailed protocol for the application of FFE for proteins and peptides, see Moritz and Simpson (57).

In chromatofocusing, usually a weak anion exchanger is used as the matrix in which the functional groups are amines, and the eluent is a buffer containing a large number of buffering species, which together give a uniform buffering capacity over a broad pH range. Unlike ion-exchange chromatography, in which a pH gradient is normally formed using a gradient mixer, chromatofocusing takes advantage of the buffering action of the charged functional groups on the matrix, and the pH gradient is formed automatically as the eluting buffer titrates the functional groups on the matrix. As elution progresses, the pH at each point in the column is gradually lowered, and proteins with different pI values will migrate at different distances on the column before binding. In this way, proteins elute in the order of their pI s (58). Yan and colleagues (59) used chromatofocusing coupled to nonporous (NPS) RP-HPLC for fractionating and comparing protein expression using a drug-treated cell line vs the same untreated cell line. This method provides a 2D map based on pI values and hydrophobicity and has been shown to be highly reproducible for quantitative differential expression analysis. Soldi and colleagues (60) used a commercial platform combining chromatofocusing and NPS RP-HPLC for protein profiling of human urine and showed that this method could be a complementary system to 2-DE in body fluid research.

2.3.2.2. 2D ELECTROPHORESIS

2-DE has been the most commonly used technique in the field of proteomics since its development in 1975 by O'Farrell (26) and Klose (27). This technique couples IEF in the first dimension with SDS-PAGE in the second dimension and allows the separation of complex mixtures of proteins according to their respective pI and M_r values. Depending on the gel size and pH gradient used, 2-DE can resolve more than 5000 proteins simultaneously (more than 2000

proteins routinely) and can detect less than 1 ng of protein per spot (46). Since 2-DE has suffered from problems such as reproducibility, resolution, proteins with extremes of *pI*, and recovery of hydrophobic proteins (61), it is now seriously challenged by other non-gel-based approaches. However, as Rabilloud (31) pointed out, if the goal of the proteomic experiment is to look for quantitative changes, 2-DE will remain unrivalled for some time.

Body fluid research is closely related to finding disease biomarkers, and therefore, quantitative analysis of differentially expressed proteins in normal and disease groups is important. Although 2-DE is a good quantitative tool, its ability has been hampered by important limitations. First, the predominant protein staining methods are either not sensitive enough (Coomassie brilliant blue) or have a limited linearity (silver staining) (62). The application of radioactive labeling or fluorescent stains can alleviate these problems, but only partially. Second, the intrinsic gel-to-gel variation of 2-DE masks the biological difference between the samples and compromises any quantitative comparison of protein expression levels (63). DIGE (64) circumvents many of the issues associated with traditional 2-DE, such as reproducibility and limited dynamic range, and allows for more accurate and sensitive quantitative analysis (65).

In DIGE, two samples are labeled *in vitro* using two different fluorescent cyanine dyes (CyDyes; Amersham Biosciences) differing in their excitation and emission wavelengths, then mixed before IEF, and separated on a single 2D gel. After consecutive excitation with both wavelengths, the images are overlaid and subtracted (normalized), whereby especially differences (e.g., up- or down-regulated, and/or posttranslationally modified proteins) between the two samples can be visualized (46). This multiplex approach instead of the “one gel one sample” approach solves most of the problems associated with gel-to-gel variation, spot matching, and normalization. In addition, CyDye has a detection limit of 150 to 500 pg for a single protein with a linear response in protein concentration over 5 orders of magnitude, whereas silver staining has a protein detection limit of approx 1 ng with a dynamic range of less than 2 orders of magnitude (65). At least five replicate gels should be run per sample for quantitative analysis in traditional 2-DE, and owing to the high variability from sample comparisons run in different gels, the threshold for accepting a meaningful variation is set at a factor of 2.0 (100% variation) (66). In contrast, DIGE can detect quantitative changes as low as 10% with 95% confidence, and the use of an internal standard helps to minimize false positives and negatives (25).

For biomarker research using body fluids, protein profiling of a large set of samples is essential. In this case, the primary benefit of sample multiplexing is that a pooled standard can be included on each gel, which comprises equal amounts of each sample and represents the average of all the samples being analyzed. The pooled standard approach is used to normalize protein abundance

Table 2
Commonly Used Liquid Chromatography Methods in Proteomics

Principle of separation	Type of chromatography
Size and shape	Size-exclusion chromatography (gel-filtration or gel-permeation chromatography)
Net charge	Ion-exchange chromatography
Hydrophobicity	Hydrophobic interaction chromatography Reversed-phase high-performance liquid chromatography
Antigen-antibody interaction	Immunoaffinity chromatography
Isoelectric point (pI)	Chromatofocusing
Metal binding	Immobilized metal ion affinity chromatography

measurements across multiple gels in an experiment, making it possible to compare more than two samples accurately (67). A more detailed review of multiplexed dye technologies is presented by Patton in chapter 4.

2.3.2.3. LIQUID CHROMATOGRAPHY

Chromatography is a widely used technique for separating the components of a mixture by allowing the sample (the analyte) to distribute between the stationary and mobile phases. Stationary phases, the key elements of LC, are made of the support matrix chemically coated with a bonded phase containing functional groups that provide the desired specific binding interaction (68). **Table 2** summarizes commonly used chromatographic methods and their principles of separation. Chromatography can be used for the enrichment of low-abundance proteins as well as for multidimensional analysis of body fluids. For a more detailed review of chromatographic methods for separating proteins and peptides, see Simpson (32) and Mant and Hodges (44).

2.3.2.3.1. Chromatographic Prefractionation for 2-DE. As mentioned above, immunoaffinity chromatography is the most commonly used prefractionation tool in body fluid research. However, other chromatographic methods such as ion-exchange chromatography and RP-HPLC can also be considered for prefractionation. Combining a chromatographic step with 2-DE provides a third orthogonal dimension for protein separation. For example, if we use RP-HPLC before 2-DE, we are separating proteins based on a combination of their hydrophobicity, pI , and M_r . For an overview of chromatographic prefractionation prior to 2-DE, see Lescuyer et al. (69).

2.3.2.3.2. Multidimensional Analysis Using Chromatography. As we discussed in chromatofocusing, multiple chromatographic methods can be coupled for separating the components of a mixture (e.g., combination of chromatofocusing